Efavirenz/lamivudine/tenofovir disoproxil

Efavirenz/lamivudine/tenofovir disoproxil is a fixed-dose combination antiretroviral medication used in the treatment and prevention of HIV/AIDS. It combines three antiretroviral agents: efavirenz, lamivudine, and tenofovir disoproxil.

Composition

The medication is composed of three active ingredients: efavirenz, lamivudine, and tenofovir disoproxil. Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI), lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI), and tenofovir disoproxil is a nucleotide reverse transcriptase inhibitor (NtRTI).

Mechanism of Action

Each component of the Efavirenz/lamivudine/tenofovir disoproxil combination works by inhibiting the action of the reverse transcriptase enzyme, an essential protein that the HIV virus uses to replicate its genetic material. By blocking this enzyme, the medication prevents the virus from multiplying, thereby reducing the amount of virus in the body.

Usage

Efavirenz/lamivudine/tenofovir disoproxil is used as part of antiretroviral therapy (ART) for the treatment of HIV infection. It is also used as a preventive measure in individuals at high risk of HIV infection.

Side Effects

Common side effects of Efavirenz/lamivudine/tenofovir disoproxil include nausea, vomiting, diarrhea, and headache. Serious side effects may include liver problems, lactic acidosis, and severe skin reactions.

Interactions

Efavirenz/lamivudine/tenofovir disoproxil can interact with other medications, including other antiretroviral drugs, antacids, and certain antibiotics and antifungal medications. It is important to inform healthcare providers of all medications being taken to avoid potential drug interactions.

See Also

• Antiretroviral therapy
• HIV/AIDS
• Efavirenz
• Lamivudine
• Tenofovir disoproxil